A5006709022- Parkinson's Disease Mechanisms and Treatments
- Neurological disorders and treatments
- Alzheimer's disease research and treatments
- Dementia and Cognitive Impairment Research
- Neurological diseases and metabolism
- Genetic Neurodegenerative Diseases
- Botulinum Toxin and Related Neurological Disorders
- Amyotrophic Lateral Sclerosis Research
- Nuclear Receptors and Signaling
- Ginkgo biloba and Cashew Applications
- Advanced Neuroimaging Techniques and Applications
- Cerebral Palsy and Movement Disorders
- Functional Brain Connectivity Studies
- Autism Spectrum Disorder Research
- Advanced MRI Techniques and Applications
- Neurological and metabolic disorders
- Health Systems, Economic Evaluations, Quality of Life
- Neurobiology of Language and Bilingualism
- RNA regulation and disease
- Neuroscience and Neuropharmacology Research
- Neuroinflammation and Neurodegeneration Mechanisms
- Restless Legs Syndrome Research
- Balance, Gait, and Falls Prevention
- Attention Deficit Hyperactivity Disorder
- CAR-T cell therapy research
University of California, San Diego
2016-2025
Parkinson's UK
1994-2024
VIB-UAntwerp Center for Molecular Neurology
2021-2024
University of Antwerp
2021-2024
University of California, Los Angeles
2000-2024
University of California System
2024
University of Iowa
2009-2024
Rutgers, The State University of New Jersey
2024
University of Pennsylvania
2024
University of California, San Francisco
2016-2024
Background: PSP is a neuropathologically defined disease entity. Clinical diagnostic criteria, published in 1996 by the National Institute of Neurological Disorders and Stroke/Society for PSP, have excellent specificity, but their sensitivity limited variant syndromes with presentations other than Richardson's syndrome. Objective: We aimed to provide an evidence- consensus-based revision clinical criteria PSP. Methods: searched PubMed, Cochrane, Medline, PSYCInfo databases articles English...
Current criteria for the clinical diagnosis of pathologically confirmed corticobasal degeneration (CBD) no longer reflect expanding understanding this disease and its clinicopathologic correlations. An international consortium behavioral neurology, neuropsychology, movement disorders specialists developed new based on consensus a systematic literature review. Clinical diagnoses (early or late) were identified 267 nonoverlapping CBD cases from published reports brain banks. Combined with...
As there are no biological markers for the antemortem diagnosis of degenerative parkinsonian disorders, currently relies upon presence and progression clinical features confirmation depends on neuropathology. Clinicopathologic studies have shown significant false-positive false-negative rates diagnosing these misdiagnosis is especially common during early stages diseases. It important to establish a set widely accepted diagnostic criteria disorders that may be applied reproduced in blinded...
We describe two extended haplotypes that cover the human tau gene. In a total of ∼200 unrelated caucasian individuals there is complete disequilibrium between polymorphisms which span gene (which covers ∼100 kb DNA). This suggests establishment was an ancient event and either recombination suppressed in this region, or recombinant genes are selected against. Furthermore, we show more common haplotype (H1) significantly over-represented patients with progressive supranuclear palsy (PSP),...
Chronic traumatic encephalopathy (CTE) is a neurodegeneration characterized by the abnormal accumulation of hyperphosphorylated tau protein within brain. Like many other neurodegenerative conditions, at present, CTE can only be definitively diagnosed post-mortem examination brain tissue. As first part series consensus panels funded NINDS/NIBIB to define neuropathological criteria for CTE, preliminary were used 7 neuropathologists blindly evaluate 25 cases various tauopathies, including...
Abstract There is controversy regarding the definition and characteristics of mild cognitive impairment in Parkinson's disease. The Movement Disorder Society commissioned a Task Force to critically evaluate literature determine frequency disease–mild its association with dementia. A comprehensive PubMed review was conducted using systematic inclusion exclusion criteria. mean 26.7% (range, 18.9%–38.2%) nondemented patients disease have impairment. increases age, duration, severity....
A working group supported by the Office of Rare Diseases National Institutes Health formulated neuropathologic criteria for corticobasal degeneration (CBD) that were subsequently validated an independent neuropathologists. The do not require a specific clinical phenotype, since CBD can have diverse presentations, such as progressive asymmetrical rigidity and apraxia, aphasia, or frontal lobe dementia. Cortical atrophy, ballooned neurons, substantia nigra been emphasized in previous...
If depression is associated with apathy, then they should be expressed together in different dementia syndromes and co-occur at varying levels of disease severity. The authors performed a cross-sectional comparison neuropsychiatric symptoms 30 Alzheimer's disease, 28 frontotemporal dementia, 40 Parkinson's 34 Huntington's 22 progressive supranuclear palsy patients, using standardized rating scale (the Neuropsychiatric Inventory). Apathy did not correlate the combined sample; apathy (r =...
We investigated the validity and reliability of diagnoses made by eight neuropathologists who used preliminary NINDS neuropathologic diagnostic criteria for progressive supranuclear palsy (PSP) related disorders. The specific disorders were typical, atypical, combined PSP, postencephalitic parkinsonism, corticobasal ganglionic degeneration, Pick's disease. These chosen because difficulties in their differentiation. assessed measuring sensitivity positive predictive value. Reliability was...